ZA201803035B - Biomarker of polycystic kidney disease and uses thereof - Google Patents
Biomarker of polycystic kidney disease and uses thereofInfo
- Publication number
- ZA201803035B ZA201803035B ZA2018/03035A ZA201803035A ZA201803035B ZA 201803035 B ZA201803035 B ZA 201803035B ZA 2018/03035 A ZA2018/03035 A ZA 2018/03035A ZA 201803035 A ZA201803035 A ZA 201803035A ZA 201803035 B ZA201803035 B ZA 201803035B
- Authority
- ZA
- South Africa
- Prior art keywords
- biomarker
- kidney disease
- polycystic kidney
- polycystic
- disease
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 208000030761 polycystic kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257089P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062075 WO2017087409A1 (en) | 2015-11-18 | 2016-11-15 | Biomarker of polycystic kidney disease and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201803035B true ZA201803035B (en) | 2019-02-27 |
Family
ID=57539614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/03035A ZA201803035B (en) | 2015-11-18 | 2018-05-09 | Biomarker of polycystic kidney disease and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11116755B2 (enExample) |
| EP (1) | EP3377908B1 (enExample) |
| JP (1) | JP6895963B2 (enExample) |
| KR (1) | KR20180083902A (enExample) |
| CN (1) | CN108700594B (enExample) |
| AU (1) | AU2016357720A1 (enExample) |
| BR (1) | BR112018009879A2 (enExample) |
| CO (1) | CO2018006126A2 (enExample) |
| EA (1) | EA201891170A1 (enExample) |
| MX (1) | MX2018006250A (enExample) |
| WO (1) | WO2017087409A1 (enExample) |
| ZA (1) | ZA201803035B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| PL3920912T3 (pl) * | 2019-02-04 | 2025-11-12 | Genzyme Corporation | Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
| JPWO2023145898A1 (enExample) * | 2022-01-27 | 2023-08-03 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710227B1 (en) | 1998-09-16 | 2004-03-23 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
| ATE318818T1 (de) | 1998-06-16 | 2006-03-15 | Us Gov Health & Human Serv | Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen |
| US6559152B2 (en) | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| JP2003500418A (ja) | 1999-05-24 | 2003-01-07 | エイブイアイ バイオファーマ， インコーポレイテッド | 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| WO2001081348A1 (en) | 2000-04-25 | 2001-11-01 | Bristol-Myers Squibb Company | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| AU2509602A (en) | 2000-12-20 | 2002-07-01 | Sod Conseils Rech Applic | Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2003063764A2 (en) | 2001-07-10 | 2003-08-07 | Bristol-Myers Squibb Pharma Company | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002573A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| MXPA05002572A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina. |
| NZ539164A (en) | 2002-09-04 | 2006-04-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1694705A (zh) | 2002-09-04 | 2005-11-09 | 先灵公司 | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2499639C (en) | 2002-09-19 | 2011-11-08 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| CA2499593C (en) | 2002-09-19 | 2011-08-16 | Michael P. Dwyer | Pyrazolopyridines as cyclin dependent kinase inhibitors |
| JP2006503838A (ja) | 2002-09-23 | 2006-02-02 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン |
| ATE377600T1 (de) | 2002-09-23 | 2007-11-15 | Schering Corp | Imidazopyrazine als cdk-inhibitoren |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| JP5661457B2 (ja) | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
| US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| CN107935983A (zh) | 2008-10-03 | 2018-04-20 | 简詹姆公司 | 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂 |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| NZ625712A (en) | 2009-11-27 | 2016-02-26 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| US20110195903A1 (en) | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
| US20140079769A1 (en) | 2010-10-01 | 2014-03-20 | Fabiola Terzi | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| JP6021021B2 (ja) | 2010-11-05 | 2016-11-02 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
| SG11201401222WA (en) | 2011-10-03 | 2014-09-26 | Celmatix Inc | Methods and devices for assessing risk to a putative offspring of developing a condition |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN102590491B (zh) | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途 |
| ES2982997T3 (es) | 2012-07-03 | 2024-10-21 | Fond Centro San Raffaele | 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JP6730252B2 (ja) | 2014-08-04 | 2020-07-29 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
-
2016
- 2016-11-15 US US15/775,736 patent/US11116755B2/en active Active
- 2016-11-15 CN CN201680079045.XA patent/CN108700594B/zh active Active
- 2016-11-15 EA EA201891170A patent/EA201891170A1/ru unknown
- 2016-11-15 WO PCT/US2016/062075 patent/WO2017087409A1/en not_active Ceased
- 2016-11-15 JP JP2018525768A patent/JP6895963B2/ja active Active
- 2016-11-15 MX MX2018006250A patent/MX2018006250A/es unknown
- 2016-11-15 BR BR112018009879A patent/BR112018009879A2/pt not_active Application Discontinuation
- 2016-11-15 EP EP16809582.6A patent/EP3377908B1/en active Active
- 2016-11-15 AU AU2016357720A patent/AU2016357720A1/en not_active Abandoned
- 2016-11-15 KR KR1020187016766A patent/KR20180083902A/ko not_active Withdrawn
-
2018
- 2018-05-09 ZA ZA2018/03035A patent/ZA201803035B/en unknown
- 2018-06-15 CO CONC2018/0006126A patent/CO2018006126A2/es unknown
-
2021
- 2021-08-17 US US17/404,701 patent/US12150938B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210379031A1 (en) | 2021-12-09 |
| EP3377908A1 (en) | 2018-09-26 |
| US11116755B2 (en) | 2021-09-14 |
| MX2018006250A (es) | 2018-09-05 |
| KR20180083902A (ko) | 2018-07-23 |
| US12150938B2 (en) | 2024-11-26 |
| CN108700594B (zh) | 2021-06-29 |
| US20180338961A1 (en) | 2018-11-29 |
| AU2016357720A1 (en) | 2018-07-05 |
| JP2019502902A (ja) | 2019-01-31 |
| WO2017087409A1 (en) | 2017-05-26 |
| EP3377908B1 (en) | 2020-08-05 |
| CN108700594A (zh) | 2018-10-23 |
| EA201891170A1 (ru) | 2018-11-30 |
| CO2018006126A2 (es) | 2018-07-10 |
| JP6895963B2 (ja) | 2021-06-30 |
| BR112018009879A2 (pt) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255238A0 (en) | Combinations of cannabinoids and acyl-ethanol-amines | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| EP3259594A4 (en) | Biomarkers of myocardial injury | |
| GB201614455D0 (en) | Biomarkers | |
| IL251204A0 (en) | Biomarkers and predictive methods | |
| SI3154526T1 (sl) | Trdne oblike sofosbuvira | |
| GB201400521D0 (en) | Biomarker and uses thereof | |
| IL265628A (en) | Solid state forms of valbenazine | |
| GB201719639D0 (en) | Setection of biomarkers | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| EP3338088A4 (en) | BIOMARKER FOR CORONARY DISEASE | |
| IL261906A (en) | Biomarkers for proteopathies and their uses | |
| ZA201803035B (en) | Biomarker of polycystic kidney disease and uses thereof | |
| PT3325135T (pt) | Método de condicionamento de membranas | |
| IL265180B (en) | New polymorphs and new solid states of tiacomycin b | |
| EP3200825A4 (en) | Antibodies against pathological forms of tdp-43 and uses thereof | |
| SG11201700290SA (en) | Biomarkers of polycystic kidney disease and uses thereof | |
| GB2544217B (en) | Chlorination of sucrose-6-esters | |
| GB201600964D0 (en) | Determination of vehicle capabilities | |
| IL254666A0 (en) | Crystalline forms of Aldecalcitol | |
| HK1259877A1 (en) | Biomarker of polycystic kidney disease and uses thereof | |
| FR3016113B1 (fr) | Drague de coquillages | |
| HK1236618A1 (en) | Biomarkers of polycystic kidney disease and uses thereof | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir |